Manufactured by: Beximco Pharmaceuticals Ltd.
Mebhydrolin Similar medicine
Bexidal is indicated for Allergic conditions
Closed-angle glaucoma; urinary retention, prostatic hyperplasia or pyloroduodenal obstruction; epilepsy. Elderly. Pregnancy. May impair ability to drive or operate machinery.
CNS depression; paradoxical stimulation (high doses, children or elderly); headache, psychomotor impairment; dry mouth, thickened respiratory tract secretions, blurred vision; urinary difficulty or retention, constipation, increased gastric reflux; nausea, vomiting, diarrhoea, epigastric pain. Rarely, blood disorders. Convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, sleep disturbances, depression, confusion, tinnitus, hypotension, hair loss.
Potentially Fatal: Anaphylaxis.
Enhanced sedation with alcohol or other CNS depressants. Additive antimuscarinic effects with MAOIs, atropine, TCAs. May mask warning symptoms caused by ototoxic agents e.g. aminoglycoside antibiotics.
Premature infants and neonates. Acute asthmatic attack.
Mebhydrolin is an ethylenediamine derivative antihistamine with antimuscarinic and sedative properties.
Adults and children over 10 years: 2-6 tablets daily
Children 5-10 years: 2-4 tablets daily
Children 2-5 years: 1-3 tablets daily
Children upto 2 years: 1-2 tablets daily
FDA has not yet classified the drug into a specified pregnancy category.